Karn Wijarnpreecha1, Charat Thongprayoon2, Pitchaphon Nissaisorakarn3, Veeravich Jaruvongvanich4, Kiran Nakkala5, Ridhmi Rajapakse2, Wisit Cheungpasitporn6. 1. Department of Internal Medicine, Bassett Medical Center, One Atwell Road, Cooperstown, NY, 13326, USA. dr.karn.wi@gmail.com. 2. Department of Internal Medicine, Bassett Medical Center, One Atwell Road, Cooperstown, NY, 13326, USA. 3. Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. 4. Department of Internal Medicine, University of Hawaii, Honolulu, HI, USA. 5. Cape Fear Center for Digestive Disease, P.A., Fayetteville, NC, USA. 6. Division of Nephrology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND/ OBJECTIVES: The reported risk of chronic kidney disease (CKD) in patients with Helicobacter pylori infection is conflicting. This meta-analysis was conducted to summarize all available data and to estimate the prevalence and association between H. pylori and kidney disease and CKD. METHODS: Comprehensive literature review was conducted using MEDLINE and EMBASE database through October 2016 to identify studies that reported the prevalence or the association between H. pylori infection and non-dialysis-dependent kidney diseases or CKD. Effect estimates from the individual study were extracted and combined using random-effect, generic inverse variance method of DerSimonian and Laird. RESULTS: Of 4546 studies, nine cross-sectional studies met the eligibility criteria and were included in the meta-analysis. The estimated prevalence of H. pylori infection among subjects with kidney disease was 53% (95% CI 45-61%). The pooled OR of H. pylori in patients with non-dialysis-dependent kidney diseases was 1.20 (95% CI 0.73-1.97) when compared with the patients without kidney diseases. The meta-analysis was then limited to only studies evaluating the risk of H. pylori in CKD; the pooled OR of H. pylori in patients with CKD was 1.00 (95% CI 0.58-1.71). CONCLUSIONS: The estimated prevalence of H. pylori in patients with non-dialysis-dependent kidney diseases is 53%. This study does not support the association between H. pylori infection and non-dialysis-dependent kidney diseases nor CKD.
BACKGROUND/ OBJECTIVES: The reported risk of chronic kidney disease (CKD) in patients with Helicobacter pylori infection is conflicting. This meta-analysis was conducted to summarize all available data and to estimate the prevalence and association between H. pylori and kidney disease and CKD. METHODS: Comprehensive literature review was conducted using MEDLINE and EMBASE database through October 2016 to identify studies that reported the prevalence or the association between H. pyloriinfection and non-dialysis-dependent kidney diseases or CKD. Effect estimates from the individual study were extracted and combined using random-effect, generic inverse variance method of DerSimonian and Laird. RESULTS: Of 4546 studies, nine cross-sectional studies met the eligibility criteria and were included in the meta-analysis. The estimated prevalence of H. pyloriinfection among subjects with kidney disease was 53% (95% CI 45-61%). The pooled OR of H. pylori in patients with non-dialysis-dependent kidney diseases was 1.20 (95% CI 0.73-1.97) when compared with the patients without kidney diseases. The meta-analysis was then limited to only studies evaluating the risk of H. pylori in CKD; the pooled OR of H. pylori in patients with CKD was 1.00 (95% CI 0.58-1.71). CONCLUSIONS: The estimated prevalence of H. pylori in patients with non-dialysis-dependent kidney diseases is 53%. This study does not support the association between H. pyloriinfection and non-dialysis-dependent kidney diseases nor CKD.
Authors: Gerardo Nardone; Alba Rocco; Maria Fiorillo; Mariassunta Del Pezzo; Giovanni Autiero; Rosario Cuomo; Giovanni Sarnelli; Antonietta Lambiase; Gabriele Budillon; Bruno Cianciaruso Journal: Helicobacter Date: 2005-02 Impact factor: 5.753
Authors: Raúl Herzog; María José Álvarez-Pasquin; Camino Díaz; José Luis Del Barrio; José Manuel Estrada; Ángel Gil Journal: BMC Public Health Date: 2013-02-19 Impact factor: 3.295